The trajectory of Viagra, formerly marketed by copyright, presents a fascinating case study for stakeholders considering the pharmaceutical sector. Despite its early success and generation of vast in sales, the exclusivity lapse has opened the floodgates for alternative medications, substantially eroding income opportunities. This transition raises